Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1

Interventions

Cyclophosphamide 44Biopsy 35Specimen Handling 34Magnetic Resonance Spectroscopy 30fludarabine 27aldesleukin 26Filgrastim 20Carboplatin 20Paclitaxel 19fludarabine phosphate 17Rituximab 17Sirolimus 16Cisplatin 16Temozolomide 15Radiotherapy 14Etoposide 14Bevacizumab 14Prednisone 13Gemcitabine 13Docetaxel 13Cytarabine 13Erlotinib Hydrochloride 12Fluorouracil 11Vorinostat 10Vincristine 10Sorafenib 10Electrocardiography 10Doxorubicin 10temsirolimus 9pembrolizumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00924170 2023-11-14

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 30 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡